BACKGROUND: Patterns of care of physician specialists may differ for patients with hepatocellular carcinoma (HCC). Reasons underlying variations are poorly understood. One source of variation may be disparate referral rates to specialists, leading to differences in cancer-directed treatments. STUDY DESIGN: Surveillance, Epidemiology, and End Results (SEER)-linked Medicare database was queried for patients with HCC, diagnosed between 1998 and 2007, who consulted 1 or more physicians after diagnosis. Visit and procedure records were abstracted from Medicare billing records. Factors associated with specialist consult and subsequent treatment were examined. RESULTS: There were 6,752 patients with HCC identified; 1,379 (20%) patients had early-stage disease. Median age was 73 years; the majority were male (66%), white (60%), and from the West region (56%). After diagnosis, referral to a specialist varied considerably (hepatology/gastroenterology, 60%; medical oncology, 62%; surgery, 56%; interventional radiology [IR], 33%; radiation oncology, 9%). Twenty-two percent of patients saw 1 specialist; 39% saw 3 or more specialists. Time between diagnosis and visitation with a specialist varied (surgery, 37 days vs IR, 55 days; p = 0.04). Factors associated with referral to a specialist included younger age (odds ratio [OR] 2.16), Asian race (OR 1.49), geographic region (Northeast OR 2.10), and presence of early-stage disease (OR 2.21) (all p < 0.05). Among patients with early-stage disease, 77% saw a surgeon, while 50% had a consultation with medical oncologist. Receipt of therapy among patients with early-stage disease varied (no therapy, 30%; surgery, 39%; IR, 9%; chemotherapy, 23%). Factors associated with receipt of therapy included younger age (OR 2.48) and early-stage disease (OR 2.20). CONCLUSIONS: After HCC diagnosis, referral to a specialist varied considerably. Both clinical and nonclinical factors were associated with consultation. Disparities in referral to a specialist and subsequent therapy need to be better understood to ensure all HCC patients receive appropriate care.
BACKGROUND: Patterns of care of physician specialists may differ for patients with hepatocellular carcinoma (HCC). Reasons underlying variations are poorly understood. One source of variation may be disparate referral rates to specialists, leading to differences in cancer-directed treatments. STUDY DESIGN: Surveillance, Epidemiology, and End Results (SEER)-linked Medicare database was queried for patients with HCC, diagnosed between 1998 and 2007, who consulted 1 or more physicians after diagnosis. Visit and procedure records were abstracted from Medicare billing records. Factors associated with specialist consult and subsequent treatment were examined. RESULTS: There were 6,752 patients with HCC identified; 1,379 (20%) patients had early-stage disease. Median age was 73 years; the majority were male (66%), white (60%), and from the West region (56%). After diagnosis, referral to a specialist varied considerably (hepatology/gastroenterology, 60%; medical oncology, 62%; surgery, 56%; interventional radiology [IR], 33%; radiation oncology, 9%). Twenty-two percent of patients saw 1 specialist; 39% saw 3 or more specialists. Time between diagnosis and visitation with a specialist varied (surgery, 37 days vs IR, 55 days; p = 0.04). Factors associated with referral to a specialist included younger age (odds ratio [OR] 2.16), Asian race (OR 1.49), geographic region (Northeast OR 2.10), and presence of early-stage disease (OR 2.21) (all p < 0.05). Among patients with early-stage disease, 77% saw a surgeon, while 50% had a consultation with medical oncologist. Receipt of therapy among patients with early-stage disease varied (no therapy, 30%; surgery, 39%; IR, 9%; chemotherapy, 23%). Factors associated with receipt of therapy included younger age (OR 2.48) and early-stage disease (OR 2.20). CONCLUSIONS: After HCC diagnosis, referral to a specialist varied considerably. Both clinical and nonclinical factors were associated with consultation. Disparities in referral to a specialist and subsequent therapy need to be better understood to ensure all HCCpatients receive appropriate care.
Authors: Christopher J Sonnenday; Justin B Dimick; Richard D Schulick; Michael A Choti Journal: J Gastrointest Surg Date: 2007-10-03 Impact factor: 3.452
Authors: Jeanette C Yu; Alfred I Neugut; Shuang Wang; Judith S Jacobson; Lauren Ferrante; Vandana Khungar; Emerson Lim; Dawn L Hershman; Robert S Brown; Abby B Siegel Journal: Cancer Date: 2010-04-01 Impact factor: 6.860
Authors: Melissa M Murphy; Jessica P Simons; Sing Chau Ng; Theodore P McDade; Jillian K Smith; Shimul A Shah; Zheng Zhou; Craig C Earle; Jennifer F Tseng Journal: Ann Surg Oncol Date: 2009-08-11 Impact factor: 5.344
Authors: Maryska L G Janssen-Heijnen; Saskia Houterman; Valery E P P Lemmens; Marieke W J Louwman; Huub A A M Maas; Jan Willem W Coebergh Journal: Crit Rev Oncol Hematol Date: 2005-09 Impact factor: 6.312
Authors: Richard S Hoehn; Dennis J Hanseman; Peter L Jernigan; Koffi Wima; Audrey E Ertel; Daniel E Abbott; Shimul A Shah Journal: HPB (Oxford) Date: 2015-09 Impact factor: 3.647
Authors: Alexis P Chidi; Cindy L Bryce; Larissa Myaskovsky; Michael J Fine; David A Geller; Douglas P Landsittel; Allan Tsung Journal: Ann Surg Date: 2016-02 Impact factor: 12.969
Authors: Diamantis I Tsilimigras; J Madison Hyer; Anghela Z Paredes; Aslam Ejaz; Jordan M Cloyd; Joal D Beane; Mary Dillhoff; Allan Tsung; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2021-01-05 Impact factor: 3.452
Authors: Hans F Fuchs; Ryan C Broderick; Cristina R Harnsberger; David C Chang; Elisabeth C Mclemore; Sonia Ramamoorthy; Santiago Horgan Journal: Surg Endosc Date: 2014-12-25 Impact factor: 4.584
Authors: Yuhree Kim; Aslam Ejaz; Amit Tayal; Gaya Spolverato; John F P Bridges; Robert A Anders; Timothy M Pawlik Journal: Cancer Date: 2014-06-10 Impact factor: 6.860